Quick Answer
vTv Therapeutics Inc. reported Research And Development Expense of $17.86 million for the year ending 2025.
- vTv Therapeutics Inc. showed an increase of +54.7% in Research And Development Expense from 2024 to 2025.
- This data is from vTv Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $4.04 million | Q1 2015: $7.39 million | Q2 2015: $5.15 million | Q3 2015: $6.57 million | Q1 2016: $11.14 million | Q2 2016: $12.08 million | Q3 2016: $10.64 million | Q1 2017: $10.96 million | Q2 2017: $9.62 million | Q3 2017: $8.99 million | Q1 2018: $8.94 million | Q2 2018: $8.59 million | Q3 2018: $2.70 million | Q1 2019: $2.82 million | Q2 2019: $4.23 million | Q3 2019: $3.66 million | Q1 2020: $4.20 million | Q2 2020: $2.51 million | Q3 2020: $1.77 million | Q1 2021: $3.10 million | Q2 2021: $2.44 million | Q3 2021: $2.38 million | Q1 2022: $3.13 million | Q2 2022: $2.21 million | Q3 2022: $3.06 million | Q1 2023: $3.94 million | Q2 2023: $4.69 million | Q3 2023: $2.82 million | Q1 2024: $2.65 million | Q2 2024: $3.44 million | Q3 2024: $3.22 million | Q1 2025: $2.83 million | Q2 2025: $4.10 million | Q3 2025: $7.02 million.
- Over the full 13 years of available data (2013 to 2025), vTv Therapeutics Inc.'s Research And Development Expense has declined by 19.9%.
- Historical annual values: Fiscal year 2025: $17.86 million | Fiscal year 2024: $11.55 million | Fiscal year 2023: $13.60 million | Fiscal year 2022: $12.36 million | Fiscal year 2021: $13.32 million | Fiscal year 2020: $11.02 million | Fiscal year 2019: $15.12 million | Fiscal year 2018: $23.04 million | Fiscal year 2017: $39.64 million | Fiscal year 2016: $44.95 million | Fiscal year 2015: $27.24 million | Fiscal year 2014: $17.38 million | Fiscal year 2013: $22.29 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: